Intracoronary or intravenous infusion procedures incur 1–2 days of hospitalisation; chest discomfort and palpitations may be transiently exacerbated. Recovery to baseline functional capacity spans 2–4 weeks. Cardiac imaging baseline is established at 6–12 weeks; clinically meaningful improvement in ejection fraction or symptom scores typically emerges by 3–6 months. Patients continue standard heart-failure pharmacotherapy throughout; no medication reduction is recommended without cardiologist consensus.
Clinical trial data encompasses phase I–II safety documentation and phase II efficacy assessment across >3,000 treated patients globally. Representative studies report left-ventricular ejection fraction (LVEF) improvements of 5–10 percentage points (e.g., 25% → 35%) in 40–55% of treated cohorts over 6–12 months. Cardiac magnetic resonance imaging shows reduction in scar size and infarct zone wall thickness in responders. Exercise tolerance (6-minute walk distance, VO₂ max) improves modestly in 45–50%. Hospitalisation rates for acute decompensation decline by 25–40% in some cohorts over 12-month follow-up. Mortality benefit remains unproven in phase II; pivotal trials are ongoing.
Am I a candidate? → · Heart Failure & Cardiac Repair: full overview → · Heart Failure & Cardiac Repair cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with the Stem Plus medical team (physicians & scientists · GMP-certified Sofia laboratory · 25+ yrs international experience) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
Medicina rigenerativa certificata GMP nel cuore dell'UE — da 3.000–8.000 €, una frazione dei prezzi USA o tedeschi. Protocolli personalizzati per pazienti da oltre 50 Paesi.
Valutazione medica gratuita